CDER Compliance Director Recused From Most Duties Due To Husband's Promotion
This article was originally published in The Tan Sheet
Executive Summary
The HHS general counsel determines that to prevent potential conflicts of interest, Cynthia Schnedar must no longer handle substantive issues for compliance actions and policy.
You may also be interested in...
CDER’s New Compliance Director Sklamberg Brings Experience On Compounding Issues
Howard Sklamberg, deputy associate commissioner in FDA’s Office of Regulatory Affairs, will take over as director of the Center for Drug Evaluation and Research’s Compliance Office in January; acting compliance director Ilisa Bernstein will resume her role as deputy director.
Pink Sheet Podcast: US FDA Loses Gene Therapy Expert, Humira Biosimilars Launch, FDA Allows In-Person Meetings
Pink Sheet reporters and editors consider the impact of FDA Office of Tissues and Advanced Therapies Director Wilson Bryan’s retirement, the launch of Humira biosimilars and its effect on the biologic market, as well as the FDA moving to hybrid meetings with sponsors.
US FDA Investigating Concomitant Flu, COVID Vaccine Link To Stroke Safety Signal
No stroke risk has been identified, but FDA and CDC officials want to investigate whether concomitant administration of influenza and COVID-19 vaccines are related to the issue.